Enliven Historical Income Statement

ELVN Stock

21.68 0.18 0.84%

Historical analysis of Enliven Therapeutics income statement accounts such as Total Operating Expenses of 100.9 M or Total Other Income Expense Net of 14.4 M can show how well Enliven Therapeutics performed in making a profits. Evaluating Enliven Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Enliven Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Enliven Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enliven Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

About Enliven Income Statement Analysis

Enliven Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Enliven Therapeutics shareholders. The income statement also shows Enliven investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Enliven Therapeutics Income Statement Chart

At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 16th of February 2025, Net Interest Income is likely to grow to about 14.5 M, though Operating Income is likely to grow to (71.4 M).

Other Operating Expenses Total Operating Expenses Income Tax Expense Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Enliven Therapeutics. It is also known as Enliven Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Enliven Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 16th of February 2025, Net Interest Income is likely to grow to about 14.5 M, though Operating Income is likely to grow to (71.4 M).

	2022	2023	2024	2025 (projected)
Net Interest Income	1.1M	12.0M	13.8M	14.5M
Cost Of Revenue	622K	297K	341.6K	252.6K

Net Interest Income Cost Of Revenue

Enliven Therapeutics income statement Correlations

	Other Operating Expenses	Operating Income	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Ebit	Net Income	Selling And Marketing Expenses	Gross Profit	Cost Of Revenue	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Interest Expense
Other Operating Expenses		-0.98	1.0	-0.98	1.0	-0.95	0.43	0.86	0.8	1.0	-0.98	-0.98	0.77	-0.64	0.66	0.98	0.98	-0.97	0.9	0.85
Operating Income	-0.98		-0.98	1.0	-0.98	0.98	-0.39	-0.83	-0.82	-0.97	1.0	1.0	-0.78	0.68	-0.7	-0.95	-0.95	0.99	-0.94	-0.89
Research Development	1.0	-0.98		-0.98	1.0	-0.95	0.43	0.86	0.8	1.0	-0.98	-0.98	0.78	-0.64	0.66	0.98	0.98	-0.97	0.9	0.85
Ebitda	-0.98	1.0	-0.98		-0.98	0.98	-0.38	-0.83	-0.82	-0.97	1.0	1.0	-0.78	0.68	-0.7	-0.94	-0.94	0.99	-0.94	-0.89
Total Operating Expenses	1.0	-0.98	1.0	-0.98		-0.95	0.43	0.86	0.8	1.0	-0.98	-0.98	0.77	-0.64	0.66	0.98	0.98	-0.97	0.9	0.85
Income Before Tax	-0.95	0.98	-0.95	0.98	-0.95		-0.18	-0.74	-0.91	-0.93	0.97	0.99	-0.86	0.71	-0.73	-0.89	-0.89	0.95	-0.92	-0.87
Total Other Income Expense Net	0.43	-0.39	0.43	-0.38	0.43	-0.18		0.63	-0.13	0.49	-0.41	-0.33	-0.1	-0.03	0.04	0.52	0.52	-0.45	0.33	0.31
Income Tax Expense	0.86	-0.83	0.86	-0.83	0.86	-0.74	0.63		0.61	0.88	-0.84	-0.82	0.52	-0.38	0.41	0.88	0.88	-0.82	0.71	0.66
Depreciation And Amortization	0.8	-0.82	0.8	-0.82	0.8	-0.91	-0.13	0.61		0.75	-0.81	-0.86	0.92	-0.71	0.72	0.69	0.69	-0.76	0.78	0.73
Selling General Administrative	1.0	-0.97	1.0	-0.97	1.0	-0.93	0.49	0.88	0.75		-0.98	-0.96	0.73	-0.6	0.63	0.99	0.99	-0.97	0.89	0.84
Ebit	-0.98	1.0	-0.98	1.0	-0.98	0.97	-0.41	-0.84	-0.81	-0.98		0.99	-0.77	0.68	-0.7	-0.95	-0.95	0.99	-0.94	-0.89
Net Income	-0.98	1.0	-0.98	1.0	-0.98	0.99	-0.33	-0.82	-0.86	-0.96	0.99		-0.82	0.7	-0.72	-0.94	-0.94	0.99	-0.94	-0.89
Selling And Marketing Expenses	0.77	-0.78	0.78	-0.78	0.77	-0.86	-0.1	0.52	0.92	0.73	-0.77	-0.82		-0.74	0.74	0.7	0.7	-0.76	0.79	0.73
Gross Profit	-0.64	0.68	-0.64	0.68	-0.64	0.71	-0.03	-0.38	-0.71	-0.6	0.68	0.7	-0.74		-0.99	-0.51	-0.51	0.67	-0.77	-0.86
Cost Of Revenue	0.66	-0.7	0.66	-0.7	0.66	-0.73	0.04	0.41	0.72	0.63	-0.7	-0.72	0.74	-0.99		0.54	0.54	-0.69	0.81	0.9
Net Interest Income	0.98	-0.95	0.98	-0.94	0.98	-0.89	0.52	0.88	0.69	0.99	-0.95	-0.94	0.7	-0.51	0.54		1.0	-0.96	0.85	0.79
Interest Income	0.98	-0.95	0.98	-0.94	0.98	-0.89	0.52	0.88	0.69	0.99	-0.95	-0.94	0.7	-0.51	0.54	1.0		-0.96	0.85	0.79
Net Income From Continuing Ops	-0.97	0.99	-0.97	0.99	-0.97	0.95	-0.45	-0.82	-0.76	-0.97	0.99	0.99	-0.76	0.67	-0.69	-0.96	-0.96		-0.94	-0.9
Reconciled Depreciation	0.9	-0.94	0.9	-0.94	0.9	-0.92	0.33	0.71	0.78	0.89	-0.94	-0.94	0.79	-0.77	0.81	0.85	0.85	-0.94		0.97
Interest Expense	0.85	-0.89	0.85	-0.89	0.85	-0.87	0.31	0.66	0.73	0.84	-0.89	-0.89	0.73	-0.86	0.9	0.79	0.79	-0.9	0.97

Click cells to compare fundamentals

Enliven Therapeutics Account Relationship Matchups

Enliven Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Operating Expenses	9.3M	24.8M	38.8M	83.5M	96.1M	100.9M
Operating Income	(9.3M)	(24.8M)	(38.8M)	(83.5M)	(75.2M)	(71.4M)
Research Development	8.2M	20.5M	31.0M	64.6M	74.3M	78.0M
Ebitda	(9.3M)	(24.6M)	(38.6M)	(81.9M)	(73.7M)	(70.1M)
Total Operating Expenses	9.3M	24.8M	38.8M	83.5M	96.1M	100.9M
Income Before Tax	(19.0M)	(24.7M)	(37.7M)	(71.6M)	(64.4M)	(61.2M)
Total Other Income Expense Net	(9.6M)	22K	1.1M	11.9M	13.7M	14.4M
Income Tax Expense	(31K)	(22K)	88K	1.3M	1.5M	1.6M
Depreciation And Amortization	97K	115K	215K	297K	341.6K	358.6K
Selling General Administrative	1.1M	4.3M	7.8M	19.0M	21.8M	22.9M
Ebit	(9.4M)	(24.8M)	(38.8M)	(82.2M)	(74.0M)	(70.3M)
Net Income	(18.9M)	(24.7M)	(37.8M)	(71.6M)	(64.4M)	(61.2M)
Gross Profit	(97K)	(99K)	(622K)	(297K)	(267.3K)	(280.7K)
Cost Of Revenue	97K	99K	622K	297K	341.6K	252.6K

When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:

How To Invest In Enliven

Details

Is Enliven Stock a good investment?

Details

What is Enliven Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.89)

Return On Assets

(0.21)

Return On Equity

(0.31)

The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enliven Historical Income Statement

About Enliven Income Statement Analysis

Enliven Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Enliven Therapeutics income statement Correlations

Enliven Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enliven Therapeutics income statement Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Selling General Administrative	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income

Cost Of Revenue	- 0.99	Gross Profit
Ebit	- 0.98	Selling General Administrative
Net Income	- 0.98	Total Operating Expenses
Ebit	- 0.98	Total Operating Expenses
Total Operating Expenses	- 0.98	Ebitda
Net Income	- 0.98	Research Development